Antisense Therapeutics Limited Stock Number Of Shares Shorted
| ATHJF Stock | USD 0.04 0.00 0.00% |
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Number Of Shares Shorted Analysis
Antisense Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Antisense Therapeutics Limited has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Antisense Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 27.82 M | |||
| Shares Outstanding | 669.04 M | |||
| Shares Owned By Insiders | 19.30 % | |||
| Shares Owned By Institutions | 4.93 % | |||
| Price To Earning | (3.62) X | |||
| Price To Book | 3.05 X | |||
| Price To Sales | 24.46 X | |||
| Revenue | 1.78 M | |||
| Gross Profit | 1.71 M | |||
| EBITDA | (7.52 M) | |||
| Net Income | (5.81 M) | |||
| Cash And Equivalents | 19.23 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 227.4 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.14 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (7.81 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.67 | |||
| Market Capitalization | 41.78 M | |||
| Total Asset | 22.44 M | |||
| Retained Earnings | (53 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 5 M | |||
| Current Liabilities | 1000 K | |||
| Net Asset | 22.44 M |
About Antisense Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Antisense Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Antisense Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Antisense Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.